№ lp_1_11444
File format: docx Character count: 105691 File size: 182 KB
Year: 2024
Region / City: Australia
Topic: Medicinal Product Registration
Document Type: Submission Report
Agency: Therapeutic Goods Administration (TGA)
Author: GlaxoSmithKline Australia
Target Audience: Medical Practitioners
Treatment Phase: Initial Treatment
Indication: Myelofibrosis, including primary, post-polycythaemia vera, and post-essential thrombocythaemia myelofibrosis
Approval Status: Pending
Date of Submission: May 2024
Date of Approval: Not yet approved
Background: Momelotinib is currently approved in the UK, US, Japan, and the EU.
Description: Clinical submission for listing momelotinib under the Australian PBS for the treatment of myelofibrosis in patients with moderate to severe anaemia.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Development and Validation of HPLC Method for Simultaneous Estimation of Ondansetron Dihydrochloride, Famotidine, and Drotaverine Hydrochloride in Rabbit Plasma
Year: Not specified
Region / Country: Pakistan
Cities: Multan; Sahiwal
Field: Pharmaceutical analysis; Analytical chemistry; Pharmaceutics
Document Type: Scientific research article
Institutions: Drug Testing Laboratory Government of Punjab; Bahauddin Zakariya University Faculty of Pharmacy; Quaid-e-Azam College of Pharmacy
Authors: Rao Khurram Ayoub; Syed Nisar Hussain Shah; Asma Aslam; Romana Riaz; Naveed Nisar; Shakeel Ijaz; Aousaf Ahmad; Muneeb Ahmad
Corresponding Author: Syed Nisar Hussain Shah
Affiliation of Corresponding Author: Department of Pharmaceutics Faculty of Pharmacy Bahauddin Zakariya University Multan Pakistan; Quaid-e-Azam College of Pharmacy Sahiwal Punjab Pakistan
Keywords: HPLC; Famotidine; Drotaverine; Ondansetron; Central composite design
Analyzed Compounds: Ondansetron Dihydrochloride; Famotidine; Drotaverine Hydrochloride
Experimental Model: Rabbit plasma
Methodology: High-performance liquid chromatography with central composite design optimization
Mobile Phase Composition: Acetonitrile and phosphate buffer pH 4.8 (40:60 v/v)
Flow Rate: 1.5 mL/min
Replication: Six experimental replicates
Contact Email: [email protected]
Contact Phone: +92-334-7315016
Topics: MOMELOTINIB Omjjara dihydrochloride